ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
January 24, 2024 08:30 ET
|
Elevai Labs Inc.
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
January 17, 2024 08:30 ET
|
Elevai Labs Inc.
ELEVAI Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
January 16, 2024 08:30 ET
|
Elevai Labs Inc.
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
January 02, 2024 09:15 ET
|
Elevai Labs Inc.
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
December 11, 2023 09:15 ET
|
Elevai Labs Inc.
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
ELEVAI Labs, Inc. Expands International Distribution into Europe
December 07, 2023 09:41 ET
|
Elevai Labs Inc.
ELEVAI Labs, Inc. Expands International Distribution into Europe
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
November 29, 2023 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences
Nanomix Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy
November 29, 2022 08:30 ET
|
Nanomix Corporation
SAN LEANDRO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care (POC)...
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors
August 31, 2022 09:00 ET
|
Nanomix Corporation
SAN LEANDRO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics,...
Nanomix Receives CE Mark for its eLab COVID-19 Rapid Point-of-Care Antigen Panel
May 20, 2022 08:30 ET
|
Nanomix Corporation
EMERYVILLE, Calif, May 20, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCBB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics,...